According to Ardelyx's latest financial reports the company's current earnings (TTM) are -$65.52 M. In 2022 the company made an earning of -$67.2 M an increase over its 2021 earnings that were of -$0.16 B.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$65.52 M | -2.5% |
2022 | -$67.2 M | -57.51% |
2021 | -$0.16 B | 67.7% |
2020 | -$94.32 M | -0.34% |
2019 | -$94.64 M | 3.66% |
2018 | -$91.3 M | 44.54% |
2017 | -$63.16 M | -43.8% |
2016 | -$0.12 B | 279.04% |
2015 | -$29.65 M | 841.87% |
2014 | -$3.15 M | -50.99% |
2013 | -$6.43 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Abbott Laboratories ABT | $6.66 B | -10,270.94% | ๐บ๐ธ USA |
Amgen AMGN | $7.85 B | -12,088.71% | ๐บ๐ธ USA |
Sanofi SNY | $8.39 B | -12,913.40% | ๐ซ๐ท France |
AstraZeneca AZN | $8.49 B | -13,065.51% | ๐ฌ๐ง UK |
OPKO Health
OPK | -$0.19 B | 181.32% | ๐บ๐ธ USA |